No major increased CV risk from this DPP-4 inhibitor

Following the recent announcement of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), Consultant Endocrinologist Dr Maeve Durkan tells Lloyd Mudiwa why the results have been watched very carefully in Ireland   Consultant Endocrinologist Dr Maeve Durkan’s personal interest in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) is partly because she was initially meant to be the lead investigator for Ireland in the placebo-controlled study of the cardiovascular (CV) safety of MSD’s DPP-4 inhibitor, Januvia (sitagliptin). Although it was unfortunately not possible to get through the ethical approval process in Ireland on time for the start of the trial…